SCHEMBL3255692

SCHEMBL3255692

CC1=N[C@H](c2ccccc2)[C@H](c2ccccc2)N1C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.39
RIPK1 Q13546 3/20 0.37
POLB P06746 1/20 0.34
LMNA P02545 1/20 0.34
TSHR P16473 3/20 0.33
KDM4E B2RXH2 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33
HSD17B10 Q99714 1/20 0.33
NPSR1 Q6W5P4 2/20 0.33
PTGS2 P35354 1/20 0.33
ATM Q13315 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TP53 P04637 1/20 0.32
MDM2 Q00987 1/20 0.32
GAA P10253 1/20 0.32
DHFR P00374 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3255701 1.00 ELANE (0.39) ELANERIPK1POLBLMNATSHR
SCHEMBL3255696 1.00 ELANE (0.39) ELANERIPK1POLBLMNATSHR
SCHEMBL3253472 0.80 MAPT (0.37) ELANERIPK1POLBLMNATSHR
SCHEMBL3257489 0.80 MAPT (0.37) ELANERIPK1POLBLMNATSHR
SCHEMBL3253479 0.80 MAPT (0.37) ELANERIPK1POLBLMNATSHR
SCHEMBL3253475 0.80 MAPT (0.37) ELANERIPK1POLBLMNATSHR
Hydrochloric Acid SCHEMBL28588932 0.75 MEN1 (0.37) TSHRKDM4EMEN1KMT2AALDH1A1
SCHEMBL13386586 0.74 SMN1; SMN2 (0.35) RIPK1LMNAMEN1KMT2AALDH1A1
SCHEMBL31306917 0.73 ELANE (0.46) ELANERIPK1POLBLMNAMEN1
SCHEMBL31306878 0.73 ELANE (0.46) ELANERIPK1POLBLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7741493-B2 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives; antiinflammatory agent, neurodegenerative diseases; inflammatory bowel disease, rheumatoid arthritis and diseases associated with central nervous system, such as Alzheimer's disease AVENTIS PHARMACEUTICALS INC. (US) 2010-06-22 US disclosed
EP-1651613-B1 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS AVENTIS PHARMA INC (US) 2010-05-26 EP disclosed
US-20080132550-A1 HETEROCYCLIC COMPOUNDS AS P2X7 ION CHANNEL BLOCKERS AVENTIS PHARMACEUTICALS INC. (US) 2008-06-05 US disclosed
US-7326792-B2 Heterocyclic compounds as P2X7 ion channel blockers AVENTIS PHARMACEUTICALS INC. (US) 2008-02-05 US disclosed
US-20050026916-A1 Heterocyclic compounds as P2X7 ion channel blockers AVENTIS PHARMACEUTICALS INC. (US) 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132550-A1 HETEROCYCLIC COMPOUNDS AS P2X7 ION CHANNEL BLOCKERS P2RX3, P2RX2, P2RX5 ELANE 4363/4885RIPK1 887/4885POLB 4425/4885
US-20050026916-A1 Heterocyclic compounds as P2X7 ion channel blockers P2RX3, P2RX2, P2RX5 ELANE 4363/4885RIPK1 887/4885POLB 4425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.